
Panelists answer audience questions on treatment targets, fertility-sparing options, and formulations, and why lifestyle change and therapy pair well.

Panelists answer audience questions on treatment targets, fertility-sparing options, and formulations, and why lifestyle change and therapy pair well.

Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.

Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.

Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.

Faculty weigh the new class-wide blood pressure warning and why dropping the age-related limitation treats low testosterone as a syndrome, not aging.

Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.

Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.

Expert urologists argue that testosterone is an underused biomarker of men’s health, and review how TRAVERSE resolved longstanding cardiovascular safety concerns.

Muhammed A. Moukhtar Hammad, MBBCh, MSc, discusses real-world trends in baseline erectile dysfunction treatment across AUA sections before minimally invasive BPH procedures.

FDA expert panel members review how TRAVERSE and new evidence prompted testosterone label revisions, and what they mean for treating deficiency.

Expert urologists examine how TRAVERSE data and an FDA expert panel prompted proposed label revisions for testosterone therapy as well as what narrowed cardiovascular, prostate, and age-related restrictions mean for evaluating and treating testosterone deficiency.

Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.

Timam Niazi, MD, explains how DASL-HiCaP's salvage data sit alongside EMBARK, how his center chooses between surgery and radiation, and what the field must answer next.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

In interim data, a redesigned biopsy needle produced longer, less fragmented prostate cores, according to James S. Wysock, MD.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.

Tamim Niazi, MDCM, unpacks the interim DASL-HiCaP data, why conventional imaging was the chosen yardstick, and how to frame 96 weeks of therapy for patients.

William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.

Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.

Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how workforce gaps may affect comprehensive infertility evaluations.

Perioperative durvalumab (Imfinzi) plus 3 cycles of neoadjuvant enfortumab vedotin-ejfv (Padcev) improved survival in cisplatin-ineligible muscle-invasive bladder cancer.

Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.

Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.

Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.

Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.

Roger Li, MD, addresses the open questions surrounding adjuvant therapy after cystectomy, the urologist's role in recognizing treatment-related toxicities, and why multidisciplinary referral is the change most likely to deliver the full benefit of perioperative therapy.

Roger Li, MD, explains why patients with MIBC fall away between TURBT and a medical oncology visit, how strong urologist–oncologist relationships speed the start of neoadjuvant therapy, and how newer non-cisplatin regimens are changing referral patterns and surgical timing.

Roger Li, MD, reviews how the NIAGARA, KEYNOTE-905, KEYNOTE-B15, and VOLGA trials are moving perioperative care for muscle-invasive bladder cancer beyond cisplatin-based chemotherapy and why the data should change which patients urologists refer for neoadjuvant therapy.

Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.